• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Bristol-Myers Squibb (NY: BMY )

    50.49 +0.54 (+1.08%)
    Streaming Delayed Price Updated: 10:53 AM EDT, Sep 26, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,368,608
    Open 49.82
    Bid (Size) 50.49 (2)
    Ask (Size) 50.50 (5)
    Prev. Close 49.95
    Today's Range 49.82 - 50.55
    52wk Range 39.35 - 59.25
    Shares Outstanding 2,222,113,553
    Dividend Yield 4.52%
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    FDA Casts Doubt On Use Of Merck, Bristol Myers' PD-1 Cancer Drugs For Certain Type Of Gastric Cancer Patients
    The FDA's advisory committee is set to evaluate the use of PD-1 inhibitors in gastric cancer patients, focusing on the risks and benefits for those with varying PD-L1 levels, including low expressers. 
    Via Benzinga
    Exposures Product Safety
    Bristol Myers-2seventy Bio Halt Phase 3 Trial For Abecma In Newly Diagnosed Myeloma Patients, Speeds Path To Profitability
    2seventy bio halts enrollment in its KarMMa-9 trial for Abecma, saving $80 million and focusing on profitability by 2025. Despite the decision, the company expects strong growth following FDA approval... 
    Via Benzinga
    Exposures Product Safety

    Performance

    YTD
    -4.30%
    -4.30%
    1 Month
    +4.66%
    +4.66%
    3 Month
    +18.80%
    +18.80%
    6 Month
    -5.18%
    -5.18%
    1 Year
    -13.75%
    -13.75%

    More News

    Read More
    Analysts Think There's Still Time to Get in on Edgewise, Up 332%
    Via MarketBeat
    10 Health Care Stocks With Whale Alerts In Today's Session
    Via Benzinga
    NYSE:BMY Shows Potential for a Breakout.
    Via Chartmill
    What Analysts Are Saying About Bristol-Myers Squibb Stock
    Via Benzinga
    Current Report: Bristol-Meyers Squibb (BMY)
    Via Talk Markets
    Bristol-Myers Acquired Drug KarXT Poised For FDA Approval As First New Type Of Schizophrenia Treatment In 70 Years
    Via Benzinga
    Exposures Product Safety
    Edgewise Catapults On Surprise Victory In Cardiomyopathy; Cytokinetics Shares Dip
    Via Investor's Business Daily
    2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure?
    Via Investor's Business Daily
    Bristol Myers Squibb Presents Data For Multiple Sclerosis Drug Zeposia, Shows Long-Term Efficacy
    Via Benzinga
    New Long-Term Zeposia (ozanimod) Data Demonstrate Durable Efficacy and Consistent Safety in Relapsing Forms of Multiple Sclerosis
    From Bristol Myers Squibb
    Via Business Wire
    3 High-Yield Dividend Stocks Down by More Than 39% to Buy Now and Hold at Least a Decade
    Via The Motley Fool
    Merck Scores Two Key Victories With Keytruda In Women's Cancers
    Via Investor's Business Daily
    Bristol Myers Squibb Presents Landmark 10-Year Follow-Up Data from CheckMate -067 Which Showed Continued Durable Long-Term Survival Benefit with Opdivo® plus Yervoy® in Advanced Melanoma
    From Bristol Myers Squibb
    Via Business Wire
    Got $200? 2 Healthcare Stocks to Buy and Hold Forever
    Via The Motley Fool
    Time To Invest And Or Trade In Bio-Tech Stocks?
    Via Talk Markets
    Topics ETFs
    Bristol Myers Squibb to Report Results for Third Quarter 2024 on October 31, 2024
    From Bristol Myers Squibb
    Via Business Wire
    Bristol Myers Squibb Announces Dividend
    From Bristol Myers Squibb
    Via Business Wire
    Bernie Sanders Says If You're Poor In America You'll Live 10-15 Years Less: 'Anybody Else See A Problem With That?'
    Via Benzinga
    Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst
    Via Benzinga
    Bristol Myers Squibb to Present Data at ESMO Demonstrating Ongoing Leadership in Immuno-Oncology and Progression of Assets from Its Differentiated Research Platforms
    From Bristol Myers Squibb
    Via Business Wire
    2 Unstoppable Dividend Growth Stocks You Can Buy Now With $100
    Via The Motley Fool
    FDA Battles Backlog of Drug Factory Inspections Since COVID-19
    Via Benzinga
    Exposures Product Safety
    Bristol Myers Squibb Employees to Relay Nearly 3,000 Miles Cross-Country Aspiring to Raise Over $1 Million for the V Foundation for Cancer Research
    From Bristol Myers Squibb
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.